Replies to post #6293 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: Heparin-antithrombin binding

This graphic may help illuminate the relationship between heparin and antithrombin in anticoagulation: #msg-24393520. (I posted the graphic to explain the MoA of a drug candidate from MNTA called M118.)

The concept in the graphic is easier to understand if you bear in mind that all heparin products—unfractionated heparin as well as “low molecular weight” heparins such as Lovenox—are mixtures of short- and long-chain saccharides.

p.s. MNTA (my second largest biotech position after GTCB) is up 65% from its low in November, so December has been a good month for me so far.

[Lewis R Goudy]

>foreign surfaces of the tubing which deplete the AT3
That was what put the company on Atryn's trail over a decade
ago, ie our primeval target indication: management of heparin
resistance during extended CP bypass. The old annual reports
had a lot more technical detail than recent ones, very good
bedside reading matter.